Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study

BACKGROUND: Disease-modifying therapy is the standard treatment for patients with multiple sclerosis (MS) in remission. The primary objective of the current analysis was to assess the efficacy and safety of two teriflunomide doses (7 mg and 14 mg) in the subgroup of Chinese patients with relapsing M...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Wei, Huang, De-Hui, Hou, Shi-Fang, Zhang, Mei-Ni, Jin, Tao, Dong, Hui-Qing, Peng, Hua, Zhang, Chao-Dong, Zhao, Gang, Huang, Yi-Ning, Zhou, Dong, Wu, Wei-Ping, Wang, Bao-Jun, Li, Ji-Mei, Zhang, Xing-Hu, Cheng, Yan, Li, Hai-Feng, Li, Ling, Lu, Chuan-Zhen, Zhang, Xu, Bu, Bi-Tao, Dong, Wan-Li, Fan, Dong-Sheng, Hu, Xue-Qiang, Xu, Xian-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278187/
https://www.ncbi.nlm.nih.gov/pubmed/30511679
http://dx.doi.org/10.4103/0366-6999.246067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278187/
https://www.ncbi.nlm.nih.gov/pubmed/30511679
http://dx.doi.org/10.4103/0366-6999.246067

Ejemplares similares